Aprogen Biologics Inc. (KRX:003060)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,095.00
-60.00 (-2.78%)
Aug 12, 2026, 1:44 PM KST

Aprogen Biologics Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-131,207-170,331-104,979-118,27012,6398,103
Depreciation & Amortization
19,07719,18519,09021,3982,4042,072
Loss (Gain) From Sale of Assets
-83.59-88.69-16.15151,537-3.1-53.08
Asset Writedown & Restructuring Costs
637.76637.76154.082,271264.152,134
Loss (Gain) From Sale of Investments
10,4409,6169,934-34,724-1,380-1,623
Loss (Gain) on Equity Investments
75,69577,37729,047-75,012-1,353-352.2
Provision & Write-off of Bad Debts
47.36-0.490.01-24.29-2,224-26.23
Other Operating Activities
-9,26328,25016,98031,1641,476-720.21
Change in Accounts Receivable
3,2123,021-2,2171,218-637.92-494.75
Change in Inventory
-6,390-149.22-5,708-3,284-1,180-1,023
Change in Accounts Payable
6,212-613.74662.83-2,373313.46-155.63
Change in Other Net Operating Assets
-4,632-5,1366,056-7,55015,410-14,088
Operating Cash Flow
-36,254-38,233-30,996-33,65125,728-6,227
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-5,563-9,625-15,264-28,088-1,284-796.19
Sale of Property, Plant & Equipment
182.16210.716.5316.8216.3666.71
Cash Acquisitions
-5,080-5,080--9,223--
Divestitures
2,6212,622200-3,074-
Sale (Purchase) of Intangibles
-131.22-154.86-187.34-308.06-261.4-145.94
Investment in Securities
34,040-880.82-12,262-79,69022,19775,048
Other Investing Activities
-61,998-72,212-24,22522,086-76,742-97,329
Investing Cash Flow
-35,929-85,119-51,722-95,206-53,001-23,156

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-41,80053,95049,61020,500-
Long-Term Debt Issued
-97,97239,997114,611--
Total Debt Issued
61,476139,77293,947164,22120,500-
Short-Term Debt Repaid
--3,000-60,650-122,110-4,000-
Long-Term Debt Repaid
--1,635-61,594-353.06-262.55-349.3
Total Debt Repaid
-1,734-4,635-122,244-122,463-4,263-349.3
Net Debt Issued (Repaid)
59,742135,136-28,29741,75816,237-349.3
Issuance of Common Stock
0.610.61115,75940,0000.24-
Repurchase of Common Stock
---21.72-4,425--
Other Financing Activities
19.92-0.08-2,46837,957-455.34-0.96
Financing Cash Flow
59,762135,13784,972115,28915,782-350.26

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
584.24301.4-11.6525.0411.02
Miscellaneous Cash Flow Adjustments
----0-0
Net Cash Flow
-11,83712,0862,253-13,555-11,465-29,722

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-41,817-47,857-46,261-61,73924,444-7,023
Free Cash Flow Growth
------
Free Cash Flow Margin
-53.61%-65.36%-68.66%-70.67%37.50%-12.43%
Free Cash Flow Per Share
-3174.84-3633.40-5519.38-14680.219071.14-2642.97
Levered Free Cash Flow
-137,327-82,778-24,02613,979104,474-97,245
Unlevered Free Cash Flow
-129,072-76,091-20,57916,272104,645-97,226

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
6,4644,9302,213151.0425.7789.51
Cash Income Tax Paid
1,9291,736-31.26-2,4852,1151,810
Change in Working Capital
-1,599-2,878-1,207-11,99013,906-15,761